Enhanced antithrombotic effects with the combination of rivaroxaban - a novel, oral, direct factor Xa inhibitor and clopiclogrel, in animal models

被引：0
|
作者：
Perzborn, E. [1 ]
Fischer, E. [1 ]
Lange, U. [1 ]
机构：
[1] Bayer HealthCare, Pharma R&D Discovery Res, Wuppertal, Germany
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
220
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [41] Antithrombotic profiles of TAK-442, a novel oral factor Xa inhibitor, in venous and arterial thrombosis models
    Konishi, N.
    Hiroe, K.
    Shinozawa, E.
    Shofuda, K.
    Matsuda, K.
    Imaeda, Y.
    Fujimoto, T.
    Kubo, K.
    Kawamura, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 759 - 760
  • [42] Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis EDITOR'S COMMENT
    D'Ambrosia, Robert D.
    ORTHOPEDICS, 2012, 35 (11) : 919 - 919
  • [43] Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor in healthy subjects
    Mueck, W.
    Becka, M.
    Kubitza, D.
    Voith, B.
    Zuehlsdorf, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (06) : 335 - 344
  • [44] Concomitant administration of low-dose rivaroxaban - an oral, direct Factor Xa inhibitor - with clopidogrel and acetylsalicylic acid enhances antithrombotic efficacy in rats
    Perzborn, E.
    Fischer, E.
    Lange, U.
    Harwardt, M.
    EUROPEAN HEART JOURNAL, 2009, 30 : 331 - 332
  • [45] The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor
    Kubitza, Dagmar
    Becka, Michael
    Roth, Angelika
    Mueck, Wolfgang
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 249 - 255
  • [46] Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme
    Haas, Sylvia
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (05) : 339 - 349
  • [47] Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Zuehlsdorf, Michael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 981 - 990
  • [48] Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty
    Borris, Lars C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 1083 - 1088
  • [49] Arterial antithrombotic effect of apixaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel in rabbits
    Wong, Pancras C.
    Watson, Carol A.
    Crain, Earl J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) : E102 - E102
  • [50] In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor
    Perzborn, E
    Strassburger, J
    Wilmen, A
    Pohlmann, J
    Roehrig, S
    Schlemmer, KH
    Straub, A
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) : 514 - 521
12345